The CST3 gene product, Cystatin-C, has, however, been shown to add to creatinine’s estimate of renal function and Cystatin-C strengthens the association of eGFR with end-stage renal disease and mortality (37). This evidence concerns the gene CST3 and stage 5 chronic kidney disease.